64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms


Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).

Aim(s): Recently, we introduced 64Cu-DOTATATE PET/CT for SRI and we hypothesized that tracer uptake could be associated with overall survival (OS) and progression-free survival (PFS).

Materials and methods: We evaluated patients with NEN that had a 64Cu-DOTATATE PET/CT performed in previous prospective studies. Tracer uptake was determined as the maximal standardized uptake value (SUVmax) for each patient. Optimal cutoff for SUVmax and the hazard ratio for PFS and OS were determined. Specificity, sensitivity and accuracy were calculated for prediction of outcome at 24 months after 64Cu-DOTATATE PET/CT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carlsen E

Authors: Carlsen E, Johnbeck C, Binderup T, Loft M, Pfeifer A,

Keywords: 64Cu-dotatate, neuroendocrine neoplasm, progression-free survival, overall survival,

To read the full abstract, please log into your ENETS Member account.